Spanish plasma-derived medicines specialist Grifols (MCE: GRF) has announced positive results from its Phase II/III clinical trial evaluating the efficacy and safety of its intravenous immunoglobulin (IVIG) to treat patients with post-polio syndrome (PPS), demonstrating a significant improvement in distance walked compared to placebo.
This study met its primary endpoint of enhanced physical performance in the two-minute walk distance (2MWD) after the one-year treatment period. Patients who received monthly IVIG infusions of 1g/kg showed a statistically-significant improvement in 2MWD versus placebo. The least squares mean 2MWD change from baseline at week 52, after adjusting for differences between groups, was 12.75 meters, equating to a mean improvement of 6.07 meters over placebo.
The company noted that the immunomodulatory properties of IVIG – in this case Flebogamma 5% DIF (immune globulin intravenous [human]) – are believed to have a role in potentially improving this disabling condition.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze